Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Dec 27, 2014; 6(12): 830-835
Published online Dec 27, 2014. doi: 10.4254/wjh.v6.i12.830
Published online Dec 27, 2014. doi: 10.4254/wjh.v6.i12.830
Role of anti-angiogenesis therapy in the management of hepatocellular carcinoma: The jury is still out
Hong Sun, Department of Transplant Medicine, University Hospital Münster, 48149 Münster, Germany
Hong Sun, Man-Sheng Zhu, Wen-Rui Wu, Xiang-De Shi, Lei-Bo Xu, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Medical Research Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, Guangdong Province, China
Hong Sun, Man-Sheng Zhu, Wen-Rui Wu, Xiang-De Shi, Lei-Bo Xu, Department of Hepato-pancreato-biliary Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, Guangdong Province, China
Author contributions: Sun H and Zhu MS wrote the draft of the manuscript and contributed equally to this work; Wu WR and Shi XD collected the related references; Xu LB read through this paper and brought out several important opinions for revision.
Supported by The Special Research Foundation of the National Nature Science Foundation of China, No. 81302143; the Natural Science Foundation of Guangdong Province, China, No. S2013040015045
Correspondence to: Dr. Lei-Bo Xu, Department of Hepato-pancreato-biliary Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 107 Yan Jiang Xi Lu, Guangzhou 510120, Guangdong Province, China. mdxuleibo@hotmail.com
Telephone: +86-20-34071163 Fax: +86-20-34071091
Received: August 26, 2014
Revised: September 29, 2014
Accepted: October 28, 2014
Published online: December 27, 2014
Processing time: 118 Days and 21.1 Hours
Revised: September 29, 2014
Accepted: October 28, 2014
Published online: December 27, 2014
Processing time: 118 Days and 21.1 Hours
Core Tip
Core tip: Hepatocellular carcinoma (HCC) is a devastating disease with a high mortality rate. For a long period of time, no effective treatment options are available for patients with advanced HCC. During the last decade, molecularly targeted therapies have been introduced into the treatment of advanced HCC. However, the efficacy and safety of molecularly targeted therapies remain controversial. In addition, primary or acquired drug resistance limits the activity of molecularly targeted agents, but the underlying mechanisms have not been fully understood. This concise review aims to provide an overview of anti-angiogenesis therapy in the treatment of HCC.